{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:12:51Z","timestamp":1793319171740,"version":"4.5.0"},"reference-count":159,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Donor lymphocyte infusions (DLI) are a standard therapy following allogeneic hematopoietic cell transplantation (alloHCT) for preventing and treating leukemic relapse in high-risk patients, particularly those with myeloid malignancies such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). However, the efficacy of DLI remains suboptimal and is accompanied by a significant risk of life-threatening graft-versus-host disease (GvHD), highlighting the urgent need for strategies that enhance graft-versus-leukemia (GvL) effects while mitigating GvHD. We propose that engaging donors in an acute bout of exercise during peripheral blood lymphocyte collection represents a promising strategy to enhance GvL activity whilst mitigating the risk of GvHD. A single bout of cardiorespiratory exercise triggers catecholamine- and \u03b2\n                    <jats:sub>2<\/jats:sub>\n                    -adrenergic receptor-dependent mobilization of effector lymphocytes into the bloodstream, significantly increasing the proportion of GvL-promoting NK-cells and \u03b3\u03b4 T-cells relative to total CD3+ T-cells while reducing GvHD-promoting na\u00efve CD4+ and CD8+ T-cells. Preclinical evidence suggests that these exercise-mobilized lymphocytes infiltrate tumors, exhibit enhanced leukemic control in xenogeneic mice, and display transcriptomic and proteomic profiles indicative of heightened anti-tumor immunity, migration potential and cytokine responsiveness. In this narrative review, we evaluate the advantages and limitations of DLI as a post-alloHCT therapy and propose the novel concept of exercise-enhanced donor lymphocyte infusions (DLI-X) as a simple and cost-effective strategy to augment GvL effects in preventing and treating leukemic relapse. Additionally, we propose that enriching DLI-X with NK-cell-enhancing cytokines (e.g., IL-12, IL-15, and IL-18) will create a novel therapeutic product, termed DLI-XS, with enhanced potency for post-alloHCT applications. We also discuss how DLI-X and DLI-XS, can be leveraged in combination with other post-transplant interventions to maximize GvL effects while minimizing GvHD risks. Finally, we explore the critical role of donor fitness (e.g. V\u0307O\n                    <jats:sub>2<\/jats:sub>\n                    max) in potentially influencing clinical outcomes of alloHCT and post-transplant cell therapies. This comprehensive integration of DLI-X and DLI-XS into existing treatment paradigms represents a promising avenue for enhancing therapeutic outcomes in leukemic relapse post-alloHCT and will underscore the transformative potential of exercise as an accessible and cost-effective adjuvant for DLI.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1563972","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T01:20:44Z","timestamp":1749691244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation"],"prefix":"10.3389","volume":"16","author":[{"given":"London M.","family":"McDougal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forrest L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Katsanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328858","article-title":"The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy","volume":"15","author":"Maurer","year":"2024","journal-title":"Front Immunol"},{"key":"B2","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood J Am Soc Hematology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.8.2310.bloodjournal8282310","article-title":"Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose","volume":"82","author":"Drobyski","year":"1993","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2016.12.004","article-title":"Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect","volume":"48","author":"Orti","year":"2017","journal-title":"Exp hematology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001872","article-title":"Exercise and the immune system: taking steps to improve responses to cancer immunotherapy","volume":"9","author":"Gustafson","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00943-0","article-title":"The effect of physical exercise on anticancer immunity","volume":"24","author":"Fiuza-Luces","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/j.2040-4603.2019.tb00064.x","article-title":"Exercise training in cancer control and treatment","volume":"9","author":"Christensen","year":"2018","journal-title":"Compr Physiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2021.07.010","article-title":"Exercise and adrenergic regulation of immunity","volume":"97","author":"Simpson","year":"2021","journal-title":"Brain Behav Immun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.01.011","article-title":"Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution","volume":"23","author":"Pedersen","year":"2016","journal-title":"Cell Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.59996","article-title":"Cytotoxic T-cells mediate exercise-induced reductions in tumor growth","volume":"9","author":"Rundqvist","year":"2020","journal-title":"eLife"},{"key":"B12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","article-title":"Exercise-induced engagement of the IL-15\/IL-15R\u03b1 axis promotes anti-tumor immunity in pancreatic cancer","volume":"40","author":"Kurz","year":"2022","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bju.v131.1","article-title":"Exercise training to increase tumor natural killer-cell infiltration in men with localized prostate cancer: a randomized controlled trial","volume":"131","author":"Djurhuus","year":"2023","journal-title":"BJU Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.007","article-title":"Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: A report from the center for international blood and marrow transplant research","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.012","article-title":"Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes","volume":"28","author":"Phelan","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.4200","article-title":"The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors","volume":"99","author":"Morishima","year":"2002","journal-title":"Blood J Am Soc Hematology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2014.09.017","article-title":"Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"21","author":"Howard","year":"2015","journal-title":"Biol Blood Marrow Transplantation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3324\/haematol.2015.141119","article-title":"How to select the best available related or unrelated donor of hematopoietic stem cells","volume":"101","author":"Tiercy","year":"2016","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic Malignanices following a myeloablative conditioning: an update","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.002","article-title":"Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: A multivariable analysis including disease risk index","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic Malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.10.023","article-title":"Grade II acute graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-haploidentical transplant with post-transplant cyclophosphamide","volume":"24","author":"McCurdy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2020.11.006","article-title":"Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era","volume":"14","author":"Hong","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1200\/JCO.20.01719","article-title":"Defining the role of donor lymphocyte infusion in high-risk hematologic Malignancies","volume":"39","author":"Schmid","year":"2021","journal-title":"J Clin oncology: Off J Am Soc Clin Oncology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin oncology: Off J Am Soc Clin Oncology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588741","article-title":"CD8+ T-cell repertoire in human leukocyte antigen class I-mismatched alloreactive immune response","volume":"11","author":"Bettens","year":"2020","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.106","article-title":"Can we make a better match or mismatch with KIR genotyping","volume":"2016","author":"Mehta","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340501","article-title":"Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation","volume":"334","author":"Goulmy","year":"1996","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.A10227","article-title":"Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect","volume":"79","author":"Chen","year":"2004","journal-title":"Int J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0449-9","article-title":"G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Wen","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.11.020","article-title":"HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic Malignancies after related HLA-haploidentical bone marrow transplantation","volume":"20","author":"Zeidan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.07.016","article-title":"Improved outcome of refractory\/relapsed acute myeloid leukemia after post-transplantation cyclophosphamide-based haploidentical transplantation with myeloablative conditioning and early prophylactic granulocyte colony-stimulating factor-mobilized donor lymphocyte infusions","volume":"22","author":"Jaiswal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10570","article-title":"Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation","volume":"92","author":"Huang","year":"2007","journal-title":"Haematologica"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.193","article-title":"Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy","volume":"52","author":"Goldsmith","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/bmt.2014.217","article-title":"DLI after haploidentical BMT with post-transplant CY","volume":"50","author":"Ghiso","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/JCMA.0000000000000992","article-title":"Donor lymphocyte infusion for prophylaxis and treatment of relapse in pediatric hematologic Malignancies after allogeneic hematopoietic stem cell transplant","volume":"86","author":"Hou","year":"2023","journal-title":"J Chin Med Assoc"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.02.009","article-title":"Efficacy of azacitidine and prophylactic donor lymphocyte infusion after HSCT in pediatric patients with acute myelogenous leukemia: A retrospective pre-post study","volume":"29","author":"Booth","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v70.11","article-title":"Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post-transplant cyclophosphamide for treatment of high-risk myeloid neoplasms in children: A retrospective study","volume":"70","author":"Qi","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05145-1","article-title":"Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients","volume":"102","author":"van der Zouwen","year":"2023","journal-title":"Ann Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01785-5","article-title":"Donor lymphocyte infusion (DLI) post haploidentical stem cell transplantation (Haplo) with post-transplant cyclophosphamide (PTCy): crossing the human leukocyte antigen (HLA) barrier","volume":"57","author":"Nagler","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05276-5","article-title":"The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease","volume":"102","author":"Stadler","year":"2023","journal-title":"Ann Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2021012411","article-title":"How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy","volume":"141","author":"Biederstadt","year":"2023","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.012","article-title":"Donor lymphocyte infusions for chronic myeloid leukemia relapsing after allogeneic stem cell transplantation: may we predict graft-versus-leukemia without graft-versus-host disease","volume":"21","author":"Radujkovic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1960817","article-title":"Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed\/refractory adult T-cell acute lymphoblastic leukemia","volume":"14","author":"Baek","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14870","article-title":"T-cell-based immunotherapies for hematological cancers, part A: A SWOT analysis of immune checkpoint inhibitors (ICIs) and bispecific T-cell engagers (BiTEs)","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03595-x","article-title":"Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation","volume":"118","author":"Harada","year":"2023","journal-title":"Int J Hematology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41409-023-02137-7","article-title":"Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study","volume":"59","author":"Yang","year":"2024","journal-title":"Bone Marrow Transplantation"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2016.05.011","article-title":"Donor lymphocyte infusion after allogeneic stem cell transplantation","volume":"54","author":"Castagna","year":"2016","journal-title":"Transfusion Apheresis Science"},{"key":"B53","article-title":"CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"14","author":"Davila","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Trans Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell Malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front oncology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol medicine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.790299","article-title":"Optimization of donor lymphocyte infusion for AML relapse after allo-HCT in the era of new drugs and cell engineering","volume":"11","author":"Ye","year":"2021","journal-title":"Front oncology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0177-9","article-title":"Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity","volume":"19","author":"Duggal","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10549-017-4129-4","article-title":"Every exercise bout matters: linking systemic exercise responses to breast cancer control","volume":"162","author":"Dethlefsen","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1067369","article-title":"Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice","volume":"14","author":"Batatinha","year":"2023","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2013.10.030","article-title":"Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells","volume":"39","author":"Bigley","year":"2014","journal-title":"Brain Behav Immun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2018.08.017","article-title":"\u03b2(2)-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans","volume":"74","author":"Graff","year":"2018","journal-title":"Brain Behav Immun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2024.03.023","article-title":"A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukemia B-cells ex vivo","volume":"118","author":"Collier-Bain","year":"2024","journal-title":"Brain Behav Immun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000000914","article-title":"Intensive exercise does not preferentially mobilize skin-homing T cells and NK cells","volume":"48","author":"Turner","year":"2016","journal-title":"Med Sci Sports Exerc"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2007.08.008","article-title":"Exercise-induced redistribution of T lymphocytes is regulated by adrenergic mechanisms","volume":"22","author":"Kruger","year":"2008","journal-title":"Brain Behav Immun"},{"key":"B68","first-page":"37","article-title":"T cell homing and exercise","volume":"13","author":"Kr\u00fcger","year":"2007","journal-title":"Exerc Immunol Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2018.06.008","article-title":"Lymphocytes and monocytes egress peripheral blood within minutes after cessation of steady state exercise: A detailed temporal analysis of leukocyte extravasation","volume":"194","author":"Rooney","year":"2018","journal-title":"Physiol Behav"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2025.04.040","article-title":"Exercise-induced \u03b22-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells","volume":"128","author":"Smith","year":"2025","journal-title":"Brain Behav Immun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3775","article-title":"DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction","volume":"106","author":"Adam","year":"2005","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00264-4","article-title":"Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses","volume":"19","author":"Mocikat","year":"2003","journal-title":"Immunity"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1249\/JES.0000000000000114","article-title":"Mobilizing immune cells with exercise for cancer immunotherapy","volume":"45","author":"Simpson","year":"2017","journal-title":"Exerc Sport Sci Rev"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01217","article-title":"The graft-versus-leukemia effect in AML","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front oncology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1202950","article-title":"Beyond \u03b1\u03b2 T cells: NK, iNKT, and \u03b3\u03b4T cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML","volume":"14","author":"Kent","year":"2023","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134939","article-title":"T cell optimization for graft-versus-leukemia responses","volume":"5","author":"Biernacki","year":"2020","journal-title":"JCI Insight"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.761448","article-title":"T cell subsets in graft versus host disease and graft versus tumor","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3324\/haematol.2008.003103","article-title":"Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab","volume":"94","author":"Matthews","year":"2009","journal-title":"haematologica"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplantation"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1009143","article-title":"Selective depletion of na\u00efve T cells by targeting CD45RA","volume":"12","author":"Naik","year":"2023","journal-title":"Front Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"578741","DOI":"10.1155\/2014\/578741","article-title":"Alpha\/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors","volume":"2014","author":"R\u00e5destad","year":"2014","journal-title":"J Immunol Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00189","article-title":"Individualization of hematopoietic stem cell transplantation using alpha\/beta T-cell depletion","volume":"10","author":"R\u00e5destad","year":"2019","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1249\/00005768-199012000-00021","article-title":"Prediction of functional aerobic capacity without exercise testing","volume":"22","author":"Jackson","year":"1990","journal-title":"Med Sci Sports Exerc"},{"key":"B84","volume-title":"ACSM\u2019s guidelines for exercise testing and prescription: Eleventh Edition","year":"2021"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood J Am Soc Hematology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00595","article-title":"Relation between acute GVHD and NK cell subset reconstitution following allogeneic stem cell transplantation","volume":"7","author":"Ullrich","year":"2016","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2407-5","article-title":"NK cell therapy for hematologic Malignancies","volume":"107","author":"Mehta","year":"2018","journal-title":"Int J hematology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.12.006","article-title":"CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid Malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study","volume":"19","author":"Jaiswal","year":"2017","journal-title":"Cytotherapy"},{"key":"B91","doi-asserted-by":"publisher","first-page":"5601204","DOI":"10.1155\/2016\/5601204","article-title":"Donor cell composition and reactivity predict risk of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"2016","author":"Sairafi","year":"2016","journal-title":"J Immunol Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0728-4","article-title":"High CD4\/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched\/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia","volume":"88","author":"Xu","year":"2009","journal-title":"Ann Hematology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.10.6547","article-title":"Naive and memory T cells induce different types of graft-versus-host disease","volume":"179","author":"Dutt","year":"2007","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312751","article-title":"CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD","volume":"117","author":"Dutt","year":"2011","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012104","article-title":"Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation","volume":"2","author":"Muffly","year":"2018","journal-title":"Blood Adv"},{"key":"B96","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1249\/MSS.0000000000003130","article-title":"Clonal kinetics and single-cell transcriptional profiles of T cells mobilized to blood by acute exercise","volume":"55","author":"Z\u00fa\u00f1iga","year":"2023","journal-title":"Med Sci Sports Exerc"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2013.05.003","article-title":"The effects of age and latent cytomegalovirus infection on the redeployment of CD8+ T cell subsets in response to acute exercise in humans","volume":"39","author":"Spielmann","year":"2014","journal-title":"Brain Behav Immun"},{"key":"B98","doi-asserted-by":"publisher","first-page":"25852","DOI":"10.1038\/srep25852","article-title":"A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy","volume":"6","author":"Spielmann","year":"2016","journal-title":"Sci reports"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2022.12.002","article-title":"Applications of virus-specific T cell therapies post-BMT","volume":"60","author":"Motta","year":"2023","journal-title":"Semin Hematol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2012.160.issue-2","article-title":"Anti-tumor immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside","volume":"160","author":"Braza","year":"2013","journal-title":"Br J Hematol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.37349\/ei","article-title":"Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic Malignancies","volume":"2","author":"Jhita","year":"2022","journal-title":"Explor Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007981","article-title":"Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies","volume":"12","author":"Rao","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-011-0706-6","article-title":"\u03b3\u03b4 T-APCs: a novel tool for immunotherapy","volume":"68","author":"Moser","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-234211","article-title":"Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement","volume":"116","author":"Maniar","year":"2010","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0570","article-title":"Exercise-induced \u03b22-adrenergic receptor activation enhances the anti-leukemic activity of expanded \u03b3\u03b4 T-Cells via DNAM-1 upregulation and PVR\/Nectin-2 recognition","volume":"4","author":"Baker","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B106","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbi.2014.12.027","article-title":"Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: impact of latent cytomegalovirus infection and catecholamine sensitivity","volume":"49","author":"Bigley","year":"2015","journal-title":"Brain Behav Immun"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1005031","article-title":"Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis","volume":"13","author":"Mushtaq","year":"2022","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01534","article-title":"Cytotoxicity of donor natural killer cells to allo-reactive T cells are related with acute graft-vs.-host-disease following allogeneic stem cell transplantation","volume":"11","author":"Sheng","year":"2020","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4605.4605","article-title":"TCR diversity is a predictive marker for donor lymphocyte infusion response","volume":"128","author":"Schultze-Florey","year":"2016","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2015.08.001","article-title":"Exercise and the regulation of immune functions","volume":"135","author":"Simpson","year":"2015","journal-title":"Prog Mol Biol Trans science"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902189","article-title":"Selective mobilization of cytotoxic leukocytes by epinephrine","volume":"184","author":"Dimitrov","year":"2010","journal-title":"J Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170530093902","article-title":"Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives","volume":"24","author":"Sakkas","year":"2017","journal-title":"Curr Med Chem"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2009.03.003","article-title":"Mobilization of gammadelta T lymphocytes in response to psychological stress, exercise, and beta-agonist infusion","volume":"23","author":"Anane","year":"2009","journal-title":"Brain Behav Immun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-LB066","article-title":"Abstract LB066: Acute systemic beta-adrenergic receptor activation to improve graft composition and outcomes in hematopoietic stem cell transplantation","volume":"84","author":"Batatinha","year":"2024","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.blre.2023.101073","article-title":"Advances in NK cell therapy for hematologic Malignancies: NK source, persistence and tumor targeting","volume":"60","author":"Merino","year":"2023","journal-title":"Blood Rev"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.v5.7","article-title":"Natural killer cells in cancer immunotherapy","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm (2020)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"205796","DOI":"10.1155\/2014\/205796","article-title":"Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer","volume":"2014","author":"Romee","year":"2014","journal-title":"Scientifica (Cairo)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"115718","DOI":"10.1016\/j.biopha.2023.115718","article-title":"Cytokine-Induced Memory-Like NK Cells: Emerging strategy for AML immunotherapy","volume":"168","author":"Bakhtiyaridovvombaygi","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B119","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s13287-021-02655-5","article-title":"Cytokine-induced memory-like natural killer cells for cancer immunotherapy","volume":"12","author":"Tarannum","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201747177","article-title":"IL-12\/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation","volume":"48","author":"Song","year":"2018","journal-title":"Eur J Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Trans Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0312","article-title":"Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia","volume":"10","author":"Berrien-Elliott","year":"2020","journal-title":"Cancer Discov"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"109387","DOI":"10.1016\/j.intimp.2022.109387","article-title":"Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy","volume":"113","author":"Al-Kadhimi","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2610","article-title":"Human NK cells positively regulate gammadelta T cells in response to Mycobacterium tuberculosis","volume":"176","author":"Zhang","year":"2006","journal-title":"J Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03082","article-title":"Systemic \u03b2-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of V\u03b39V\u03b42 T-Cells","volume":"10","author":"Baker","year":"2020","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0952","article-title":"IL12\/18\/21 preactivation enhances the antitumor efficacy of expanded \u03b3\u03b4T cells and overcomes resistance to anti-PD-L1 treatment","volume":"11","author":"Teo","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17498","article-title":"Cytokine-mediated activation of human ex vivo-expanded V\u03b39V\u03b42 T cells","volume":"8","author":"Domae","year":"2017","journal-title":"Oncotarget"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01541-18","article-title":"Interferon alpha enhances NK cell function and the suppressive capacity of HIV-specific CD8+ T cells","volume":"93","author":"Kwaa","year":"2019","journal-title":"J Virol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4A0714-345RR","article-title":"Interferon-\u03b1 inhibits CD4 T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling","volume":"97","author":"Nguyen","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00280-1","article-title":"Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CML","volume":"27","author":"Moravcov\u00e1","year":"2003","journal-title":"Leuk Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.938106","article-title":"Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells","volume":"13","author":"Z\u00fa\u00f1iga","year":"2022","journal-title":"Front Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000540964","article-title":"Cytokine-induced killer cells: A unique platform for adoptive cell immunotherapy after allogeneic hematopoietic stem cell transplantation","volume":"52","author":"Rettinger","year":"2024","journal-title":"Transfus Med Hemother"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01846-9","article-title":"Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC","volume":"58","author":"Chauvet","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0104","article-title":"Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review","volume":"11","author":"Durer","year":"2019","journal-title":"Immunotherapy"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2040620721994348","DOI":"10.1177\/2040620721994348","article-title":"Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma","volume":"12","author":"Smith","year":"2021","journal-title":"Ther Adv hematology"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager (BiTE(\u00ae)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1244090","article-title":"Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell hematological cancers: a narrative review","volume":"13","author":"Collier-Bain","year":"2023","journal-title":"Front oncology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"20406207211013987","DOI":"10.1177\/20406207211013987","article-title":"Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications","volume":"12","author":"Papageorgiou","year":"2021","journal-title":"Ther Adv hematology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2018-99-113604","article-title":"Genomic determinants of response to blinatumomab in relapsed\/refractory (R\/R) B-cell precursor acute lymphoblastic leukemia in adults","volume":"132","author":"Zhao","year":"2018","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25750","article-title":"Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia","volume":"95","author":"Sterling","year":"2020","journal-title":"Am J Hematol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023660","article-title":"Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation","volume":"144","author":"Kean","year":"2024","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.836","article-title":"CTLA4Ig primed donor lymphocyte infusion: A novel approach to immunotherapy after haploidentical transplantation for advanced leukemia","volume":"25","author":"Jaiswal","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B148","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.1182\/blood-2024-205807","article-title":"Combining cytokine-induced memory-like NK cells with tafasitamab demonstrates efficacy against acute B-cell leukemia","volume":"144","author":"Filioglou","year":"2024","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03839-4","article-title":"A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion","volume":"120","author":"Nishijima","year":"2024","journal-title":"Int J Hematol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1159\/000531834","article-title":"Combination of donor lymphocyte infusion and blinatumomab for B-cell lymphoblastic lymphoma relapse after allogeneic stem-cell transplantation","volume":"16","author":"Mori","year":"2023","journal-title":"Case Rep Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.006","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.01.022","article-title":"Outcomes after donor lymphocyte infusion in patients with hematological Malignancies: donor characteristics matter","volume":"28","author":"Ros-Soto","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147645","article-title":"Donor and recipient sex in allogeneic stem cell transplantation: what really matters","volume":"101","author":"Kim","year":"2016","journal-title":"Haematologica"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.3605","article-title":"Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing","volume":"1","author":"Mandsager","year":"2018","journal-title":"JAMA Network Open"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.588453","article-title":"Characterization of Donor Variability for \u03b3\u03b4 T Cell ex vivo Expansion and Development of an Allogeneic \u03b3\u03b4 T Cell Immunotherapy","volume":"7","author":"Burnham","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B156","doi-asserted-by":"publisher","first-page":"100600","DOI":"10.1016\/j.bbih.2023.100600","article-title":"Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2","volume":"28","author":"Baker","year":"2023","journal-title":"Brain behavior Immun - Health"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S178862","article-title":"Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers","volume":"12","author":"Huang","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1986.tb02959.x","article-title":"Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist","volume":"26","author":"Leopold","year":"1986","journal-title":"J Clin Pharmacol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1182\/blood-2018-99-115420","article-title":"Donor lymphocyte infusion from G-CSF-primed, unmanipulated whole blood is safe and improves chimerism in HLA-matched and haploidentical transplantation","volume":"132","author":"G\u00f3mez-De Le\u00f3n","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1563972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T01:20:45Z","timestamp":1749691245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1563972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":159,"alternative-id":["10.3389\/fimmu.2025.1563972"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1563972","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1563972"}}